author-photo

Kwok-Hung Au

17

Papers

394

Citations

Citation Trend

Filter By

Papers (11) Sort By

Journal Conference Others

PO-1016 External validation of a nomogram for chemoirradiation in stage 2 nasopharyngeal carcinoma with IMRT

2021 Radiotherapy and Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Pseudo‐CT generation from multi‐parametric MRI using a novel multi‐channel multi‐path conditional generative adversarial network for nasopharyngeal carcinoma patients

2020 Medical Physics
Show All
- Source
- Cite
- Save
Citations (17)
Second primary cancer after intensity-modulated radiotherapy for nasopharyngeal carcinoma: A territory-wide study by HKNPCSG.

2020 Oral Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Excessive mortality in 1,353 five-year survivors of nasopharyngeal cancer.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Application of hypoglossal nerve constraint in definitive radiotherapy for nasopharyngeal carcinoma: A dosimetric feasibility study.

2020 Medical Dosimetry
Show All
- Source
- Cite
- Save
Citations (0)
Radiation-induced hypoglossal nerve palsy after definitive radiotherapy for nasopharyngeal carcinoma: Clinical predictors and dose–toxicity relationship

2019 Radiotherapy and Oncology
Show All
- Source
- Cite
- Save
Citations (6)
Constructing Novel Prognostic Biomarkers of Advanced Nasopharyngeal Carcinoma from Multiparametric MRI Radiomics Using Ensemble-Model Based Iterative Feature Selection

2019
Show All
- Source
- Cite
- Save
Citations (1)
RELAY: A multinational, double-blind, randomized Phase 3 study of erlotinib (ERL) in combination with ramucirumab (RAM) or placebo (PL) in previously untreated patients with epidermal growth factor receptor mutation-positive (EGFRm) metastatic non-small cell lung cancer (NSCLC).

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (22)
Pretreatment Prediction of Adaptive Radiation Therapy Eligibility Using MRI-Based Radiomics for Advanced Nasopharyngeal Carcinoma Patients

2019 Frontiers in Oncology
Show All
- Source
- Cite
- Save
Citations (13)
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial

2019 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (175)